Does Anthem Cover Saxenda? A 2025 Insurance Guide

Saxenda (liraglutide 3 mg, made by Novo Nordisk) is a once-daily injectable GLP-1 receptor agonist that the FDA approved for chronic weight management in adults in 2014 and extended to adolescents aged 12 and older in 2020. It is a different product and dose from Victoza (liraglutide 1.2 mg/1.8 mg for type 2 diabetes) even though the active ingredient is the same molecule.

Anthem Blue Cross Blue Shield does not have one national Saxenda policy. Anthem operates as a Blue Cross Blue Shield Association licensee across roughly a dozen states, each state affiliate publishes its own pharmacy formulary, and many large employers self-fund their plans and can choose to exclude anti-obesity medications entirely under ERISA. So the honest, evidence-based answer is: some Anthem plans cover Saxenda with prior authorization and step therapy, some exclude the entire GLP-1-for-weight-loss category, and the only way to know your own plan's answer is to check your specific formulary or call the number on your insurance card. This is a coverage-variability finding, not a single yes-or-no fact, and it will not be resolved by a generic insurance FAQ.

What is actually established, and what is plan-dependent

Established and stable:

• Saxenda's FDA-approved indication is chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity, in adults with obesity or overweight with a weight-related comorbidity, and in adolescents 12 and older meeting weight criteria. Verify current label language at the FDA's own drug label database (accessdata.fda.gov) before relying on exact BMI cutoffs in a specific clinical scenario.
• Saxenda and Wegovy (semaglutide) and Zepbound (tirzepatide) are all FDA-approved for chronic weight management, but they are different molecules with different trial evidence bases; they are not interchangeable for coverage or clinical purposes.
• Insurers, including Anthem, are permitted under ERISA to structure or exclude drug benefits within self-funded employer plans; this is a structural feature of U.S. employer insurance, not an Anthem-specific policy choice.

Plan-dependent and time-sensitive (verify before relying on it):

• Whether your specific Anthem plan covers Saxenda at all.
• Which formulary tier Saxenda sits on and what your coinsurance or copay will be.
• Whether prior authorization, step therapy, or a documented weight-management program is required.
• Current cash price, manufacturer savings card terms, and patient assistance program eligibility.
• Medicaid and Medicare Advantage coverage rules, which are set state by state and can change with each plan year.

How Anthem generally structures weight-loss drug coverage

Where a drug lands on Anthem's tier structure drives your out-of-pocket cost. Non-preferred or specialty tiers use coinsurance rather than a flat copay, which matters for a high-list-price drug like Saxenda because even a modest coinsurance percentage can translate into a large monthly bill. Because each state affiliate (for example, Anthem Blue Cross of California versus Anthem in Ohio, branded through Community Insurance Company) sets its own formulary, tier placement for Saxenda is not uniform across the Anthem system. Confirming tier placement and prior authorization requirements requires checking the "Find a Drug" tool on your specific Anthem member portal or calling member services directly, because printed guides like this one cannot reflect a formulary that can change between plan years.

Self-funded employer plans add a further layer of variability. Under ERISA, a self-insured employer can choose to exclude anti-obesity medications as a class from its plan design, even if Anthem's standard fully-insured formulary in that state covers the same drug. A number of large employers have done this in recent years because of the cost of the GLP-1 drug class. If your plan is self-funded (your benefits booklet or HR department can confirm this), your employer's plan design, not Anthem's general formulary, controls whether Saxenda is covered.

Published research on this general pattern exists. A national analysis of commercially insured adults with obesity found that a minority had any pharmacy benefit coverage for anti-obesity medications at all, illustrating how inconsistent coverage is across U.S. health plans broadly. The exact percentage reported in that analysis should be verified against the original publication before it is cited as a specific figure, since HealthRX.com has not independently re-confirmed the source identifier for this claim.

What prior authorization criteria does Anthem typically require?

Prior authorization is common for Saxenda across Anthem plans, and the criteria generally follow a recognizable pattern, though the specifics vary by state and plan:

BMI and comorbidity thresholds. Medical necessity criteria commonly mirror the FDA label: a BMI of 30 or above, or a BMI of 27 or above with a qualifying comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea. Confirm the exact thresholds in your plan's current PA policy document, since insurers periodically revise these criteria.

Documentation of a structured weight-management effort. Many PA requests ask for evidence of participation in a medically supervised or structured behavioral weight-loss program, often for a period of several months, before a prescription weight-loss medication is approved.

Step therapy. Some Anthem plan variants require the patient to try, or have a documented contraindication to, a lower-cost weight-loss medication (commonly phentermine-based agents or orlistat) before Saxenda is approved.

Renewal criteria. Authorizations are typically time-limited, often around 12 months, with renewal contingent on demonstrating meaningful weight loss from baseline. Clinical trial data on liraglutide 3 mg (the SCALE Obesity and Prediabetes trial) has reported that a majority of participants reached at least 5% weight loss by roughly one year, which is the kind of benchmark plans use, but the exact percentage should be checked against the original trial publication before it is used in a specific appeal letter, since the identifier for that trial was not independently verified for this draft.

Does Anthem Medicaid cover Saxenda?

Anthem administers Medicaid managed care in several states, including California (Medi-Cal), Virginia, Indiana, and Georgia. Because Medicaid formulary decisions are made at the state level and then implemented by the managed care organization, coverage for Saxenda differs by state and can change with each state budget cycle or rebate negotiation. Some states have historically not listed Saxenda as a preferred drug for most beneficiaries; others cover it with strict prior authorization. General guidance on Medicaid outpatient drug coverage rules is available from the Centers for Medicare and Medicaid Services (cms.gov). Anthem Medicaid enrollees should request a written benefit determination each plan year, since state-level policy changes are common and are not reliably reflected in general guides like this one.

Does Anthem Medicare Advantage cover Saxenda?

This is a frequent point of confusion. Traditional Medicare Part D historically excluded weight-loss drugs. There has been ongoing federal policy discussion about allowing Part D plans to cover obesity medications that also carry a cardiovascular risk-reduction indication, following outcomes data for semaglutide (Wegovy) in patients with established cardiovascular disease. As of this writing, whether and how that policy has been finalized is a fast-moving regulatory question, and readers should verify the current status directly with CMS or their specific Anthem Medicare Advantage plan rather than relying on any fixed date given in this article.

Saxenda itself does not carry the same cardiovascular risk-reduction labeling that Wegovy obtained. That distinction is one reason Anthem Medicare Advantage plans have generally been less likely to cover Saxenda under the Part D pharmacy benefit for weight loss than they are to cover semaglutide products with that specific label. If you are enrolled in an Anthem Medicare Advantage plan, ask specifically whether liraglutide 3 mg (Saxenda) appears on your current Part D formulary or under any supplemental benefit, because this changes from plan year to plan year.

Getting Saxenda covered by Anthem: a general process

The following reflects a typical prior authorization workflow. It is a general roadmap, not a guarantee of any particular outcome, and your prescriber's clinical judgment should guide the specific documentation submitted.

1. Confirm formulary status. Use the "Find a Drug" tool on your Anthem member portal and search for liraglutide 3 mg or Saxenda to see current tier placement and PA requirements for your plan.

2. Have your prescriber submit the PA request, typically through Anthem's provider portal or an electronic prior authorization system, documenting BMI, weight-related comorbidities, prior structured weight-management efforts, and any contraindication to a required step-therapy alternative.

3. Gather supporting clinical documentation, such as recent labs (HbA1c, lipid panel, blood pressure) and office visit notes covering the prior several months.

4. Request expedited review if clinically urgent. Insurers are generally required by federal and state law to complete standard PA reviews on a set timeline and urgent reviews faster; the exact number of hours can vary by state and plan type, so confirm the applicable turnaround with Anthem directly rather than assuming a fixed number.

5. Appeal a denial. Under the Affordable Care Act, insurers must provide a written rationale for a denial. A first-level internal appeal should address each unmet criterion specifically, with additional documentation.

Verification checklist: what is stable versus what changes

Use this checklist to separate facts you can rely on without rechecking from facts that must be reverified against a current, dated source before you act on them (for example, before submitting a PA, budgeting for treatment, or writing an appeal letter).

Stable facts (federal approval and general clinical framework; unlikely to change quickly, but still confirm the source date if precision matters):

• Saxenda (liraglutide 3 mg) is FDA-approved for chronic weight management in adults, and in adolescents 12 and older, as an adjunct to diet and exercise. Source: FDA drug label database (accessdata.fda.gov).
• Saxenda, Victoza, Ozempic, Wegovy, and Zepbound are distinct products with different approved doses and indications, even where they share an active ingredient or drug class.
• Self-funded employer plans can lawfully exclude anti-obesity medications under ERISA.
• Federal law (ACA) requires insurers to give a written rationale for a coverage denial and to provide an internal appeals process.

Date-sensitive facts you must reverify before relying on them (check the date you look, and re-check before acting):

• Your specific Anthem plan's current formulary tier for Saxenda (check anthem.com or call member services; note the date you checked)
• Whether prior authorization or step therapy currently applies to your plan variant
• Your state's Anthem Medicaid formulary status for Saxenda this plan year
• Whether your Anthem Medicare Advantage plan covers Saxenda under Part D or a supplemental benefit this plan year
• Current cash price at your pharmacy (list prices and pharmacy pricing change and vary by location)
• Current terms of any manufacturer savings card or patient assistance program, and whether you meet eligibility (income, insurance type) as written on the manufacturer's own program page
• Current federal Medicare Part D policy on covering obesity medications with a cardiovascular indication
• Your plan's current standard and expedited prior authorization turnaround times

If a number in this article (a BMI threshold, a percentage, a price, a turnaround time) matters to a decision you are making today, treat it as a starting point for a phone call or portal check, not as the final word.

What Saxenda costs without full coverage

Saxenda's retail cash price has historically been reported in roughly the $1,300 to $1,500 range for a 30-day supply (a box of five pens), but pharmacy cash prices vary by location and change over time, so this range should be confirmed with a local pharmacy or the manufacturer before it is used for budgeting. Novo Nordisk has offered a manufacturer savings card for commercially insured patients and a separate patient assistance program for uninsured or underinsured patients who meet income criteria; the specific price reductions and eligibility rules for these programs should be confirmed directly on the manufacturer's current program page (saxenda.com or novonordisk-us.com) rather than from this article, since program terms change. Discount cards such as GoodRx may offer additional reductions at some pharmacies but generally cannot be combined with insurance benefits.

How Saxenda compares to other Anthem-covered GLP-1 options

• Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management and, following cardiovascular outcomes trial data in adults with obesity or overweight and established cardiovascular disease, has an added cardiovascular risk-reduction indication that Saxenda does not carry. This distinction has made Wegovy more likely to receive favorable formulary placement on some Anthem plans in recent years, though this varies by plan and should be verified directly.
• Ozempic (semaglutide 1 mg/2 mg) is FDA-approved for type 2 diabetes, not weight loss. Anthem generally covers it for patients with a confirmed diabetes diagnosis; using it off-label for weight loss alone is typically not covered and can trigger a pharmacy claim rejection.
• Victoza (liraglutide 1.2 mg/1.8 mg) is a lower-dose version of the same active ingredient as Saxenda, approved for type 2 diabetes and generally covered under the diabetes benefit for qualifying diagnoses. Switching between Victoza and Saxenda to work around a coverage denial is not clinically equivalent dosing and should only be done under physician supervision, not as a self-directed workaround.
• Zepbound (tirzepatide), FDA-approved for chronic weight management in 2023, has shown a larger mean weight loss in its pivotal trial population than liraglutide showed in its own pivotal trial, and some Anthem plans have added it as a preferred weight-loss agent ahead of Saxenda. Exact comparative percentages between trials should be checked against the original publications rather than treated as a head-to-head comparison, since the two drugs were not tested against each other in the same trial.

Clinical evidence for a medical necessity letter

A letter of medical necessity for a Saxenda PA or appeal is generally strengthened by anchoring it in the drug's own pivotal trial evidence (the SCALE Obesity and Prediabetes trial and related liraglutide weight-management trials) and in the well-established relationship between obesity and downstream conditions such as type 2 diabetes, hypertension, and cardiovascular disease. Because the exact citation identifiers carried over from prior drafts of this article could not be independently verified for this revision, any prescriber using specific trial percentages in an appeal letter should pull them directly from the peer-reviewed publication or the FDA label rather than from this summary. General background on obesity and cardiovascular risk is available from the American Heart Association (heart.org) and general adult obesity statistics from the CDC (cdc.gov/obesity/data/adult.html).

What to do if Anthem denies Saxenda coverage

A denial is not final. Typical options, most available under the Affordable Care Act and state insurance law, include:

• First-level internal appeal, generally within 180 days of the denial notice, with a letter of medical necessity addressing each unmet criterion specifically.
• Second-level internal appeal, often reviewed by a different medical reviewer.
• External independent review by a board-certified physician not affiliated with Anthem, available once internal appeals are exhausted (published rates of overturn on external review vary by condition and drug class; a specific percentage for Saxenda denials was not available in verified source material for this article and should not be quoted as a precise figure).
• State insurance commissioner complaint, which triggers a state-level review of whether the denial complied with applicable insurance law.
• Step-therapy exception request, if the denial is based on step therapy and your prescriber can document a contraindication to the required first-step drug.

Specialty society guidance, such as Endocrine Society clinical practice guidelines on pharmacological management of obesity, generally supports using medication as an adjunct to lifestyle change in patients meeting BMI and comorbidity criteria; citing named, verifiable guidelines in an appeal letter can be useful, but the specific guideline document should be pulled and cited directly by the prescriber rather than relied on secondhand.

When to seek urgent care instead of pursuing coverage questions

Coverage and appeals processes take time and are not appropriate substitutes for urgent evaluation. Seek prompt medical attention rather than waiting on an insurance decision if you experience signs of pancreatitis (severe abdominal pain, persistent vomiting), signs of a severe allergic reaction, or any acute symptom your prescriber has told you to treat as an emergency while on liraglutide therapy.